Show simple item record

dc.contributor.authorHawarden, Amy
dc.contributor.authorRussell, Bryn
dc.contributor.authorGee, Mary Ellen
dc.contributor.authorKayali, Fatima
dc.contributor.authorClamp, Andrew
dc.contributor.authorCrosbie, Emma Jayne
dc.contributor.authorEdmondson, Richard John; orcid: 0000-0003-2553-4423; email: richard.edmondson@manchester.ac.uk
dc.date.accessioned2021-05-20T16:39:30Z
dc.date.available2021-05-20T16:39:30Z
dc.date.issued2021-04-08
dc.date.submitted2020-06-12
dc.identifierhttps://chesterrep.openrepository.com/bitstream/handle/10034/624622/additional-files.zip?sequence=2
dc.identifierhttps://chesterrep.openrepository.com/bitstream/handle/10034/624622/12885_2021_Article_8019.pdf?sequence=3
dc.identifierhttps://chesterrep.openrepository.com/bitstream/handle/10034/624622/12885_2021_Article_8019_nlm.xml?sequence=4
dc.identifier.citationBMC Cancer, volume 21, issue 1, page 378
dc.identifier.urihttp://hdl.handle.net/10034/624622
dc.descriptionFrom Springer Nature via Jisc Publications Router
dc.descriptionHistory: received 2020-06-12, accepted 2021-03-10, registration 2021-03-10, pub-electronic 2021-04-08, online 2021-04-08, collection 2021-12
dc.descriptionPublication status: Published
dc.descriptionFunder: Cancer Research UK; doi: http://dx.doi.org/10.13039/501100000289; Grant(s): 22647
dc.description.abstractAbstract: Background: Despite improvements in median survival some patients with advanced ovarian cancer die within 100 days of diagnosis; the reasons for which remain poorly understood. Here we investigate if ultra short-term survival can be explained by patient characteristics or treatment pathways. Methods: A nested case comparison study was used to examine differences between patients with high grade serous ovarian/fallopian tube cancer who died within 100 days (n = 28) compared to a comparison group of patients matched for histology and including any survival greater than 100 days (n = 134). Results: Cases and comparison patients had similar ages, BMI, ACE-27, deprivation indices, and distribution of disease on CT. There were no significant delays in time to diagnosis or treatment (p = 0.68) between the groups. However, cases had lower serum albumin, haemoglobin and higher platelet counts than matched comparison patients (p < 0.0001) and a worse performance score (P = 0.006). Conclusion: Patients who die rapidly after a diagnosis of ovarian cancer are only slightly older and have similar pre treatment frailty compared to patients whose survival approaches the median. However they do appear to undergo greater physiological compromise as a result of their disease.
dc.languageen
dc.publisherBioMed Central
dc.rightsLicence for this article: http://creativecommons.org/licenses/by/4.0/
dc.sourceeissn: 1471-2407
dc.subjectResearch Article
dc.subjectSurgical oncology, cancer imaging, and interventional therapeutics
dc.subjectOvarian cancer
dc.subjectSurvival
dc.titleFactors determining ultra-short-term survival and the commencement of active treatment in high-grade serous ovarian cancer: a case comparison study
dc.typearticle
dc.date.updated2021-05-20T16:39:30Z
dc.date.accepted2021-03-10


Files in this item

Thumbnail
Name:
additional-files.zip
Size:
79.42Kb
Format:
Unknown
Thumbnail
Name:
12885_2021_Article_8019.pdf
Size:
1.143Mb
Format:
PDF
Thumbnail
Name:
12885_2021_Article_8019_nlm.xml
Size:
74.66Kb
Format:
XML

This item appears in the following Collection(s)

Show simple item record